Actualités ac261/374645
Cytokinetics Reports Third Quarter 2024 Financial Results
Wed, 06 Nov 2024 05:00:00 GMT
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2024. Completed the ...
Cytokinetics Reports Third Quarter 2024 Financial Results
Wed, 06 Nov 2024 13:00:00 GMT
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2024. Completed ...
Cytokinetics Reports Third Quarter 2024 Financial Results
Wed, 06 Nov 2024 08:01:00 GMT
Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586 ...